NeoGenomics (NASDAQ: NEO) reported Q4 EPS of $0.06, $0.02 better than the analyst estimate of $0.04. Revenue for the quarter came in at $190.17 million versus the consensus estimate of $188.14 million.

GUIDANCE:

NeoGenomics sees FY2026 revenue of $793-801 million, versus the consensus of $796.7 million.

For earnings history and earnings-related data on NeoGenomics (NEO) click here.